Midatech Pharma : Description Report of Foreign Issuer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of, September 2019

Commission File Number 001-37652

Midatech Pharma PLC

(Translation of registrant's name into English)

Oddfellows House,

19 Newport Road,

Cardiff, CF24 0AA, United Kingdom

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-Fx Form 40-F¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

SUBMITTED HEREWITH

Attached to the Registrant's Form 6-K filing for the month of September 2019, and incorporated by reference herein, is:

Exhibit No. Description

99.1 Press release, dated September 24, 2019 entitled "Midatech Announces Filing of U.S. Shelf Registration."

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Midatech Pharma PLC
Date: September 24, 2019	By:	/s/ Stephen Stamp
			Stephen Stamp
			Chief Financial Officer

Exhibit Index

Exhibit No. Description

99.1 Press release, dated September 24, 2019 entitled "Midatech Announces Filing of U.S. Shelf Registration."

Exhibit 99.1

24 September 2019

A shelf registration statement has been filed with the United States Securities and Exchange Commission, but has not yet become effective. Any offers, solicitations of offers to buy, or sales of these securities will only be made once the shelf registration statement has been declared effective by the United States Securities and Exchange Commission, including any prospectuses and prospectus supplements. These securities may not be sold, nor may offers to buy be accepted, prior to the time that the shelf registration statement becomes effective.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which

an offer, solicitation or sale would be unlawful prior to registration and qualification under the securities law of such jurisdiction.

Midatech Pharma PLC

("Midatech" or the "Company")

Midatech Announces Filing of U.S. Shelf Registration

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, today announced that the Company has filed a "universal" shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission (the "SEC"). The filing of a shelf registration statement, a common practice by NASDAQ-listed companies, is intended to provide the Company with more timely and efficient access to the U.S. capital markets.

Once declared effective by the SEC, the shelf registration statement, which can remain effective for up to three years, will enable the Company to offer, issue and sell, in one or more offerings at any time (as long as the shelf registration statement remains effective), up to an aggregate of $50 million of ordinary shares, including American Depositary Shares ("ADSs", where each ADS represents 20 ordinary shares), warrants, and a combination of such securities, separately or as units (collectively, the "Securities"). The specifics of any future offering, including the prices and terms of any Securities offered by the Company, would be determined at the time of any such offering and would be described in detail in a prospectus supplement filed in connection with such offering.

A copy of the base prospectus included in the shelf registration statement may be obtained on the SEC's website at www.sec.gov. The filing of the shelf registration statement does not affect the statutory pre-emption rights of shareholders in the Company.

For more information, please contact:

Midatech Pharma PLC

Dr Craig Cook, CEO

Stephen Stamp, CFO

Tel: [phone]

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

James Stearns (Corporate Broking)

Tel: [phone]